ArticleFrontiers in immunology2026
Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) frequently involves extranodal sites; however, extensive skull destruction and suspected central nervous system (CNS) involvement associated with a scalp lesion are extremely rare. A 70-year-old man presented with a rapidly enlarging scalp tumor. Histopathological examination revealed diffuse proliferation of large atypical B lymphocytes consistent with a non-GCB phenotype of DLBCL. Imaging studies demonstrated a large scalp mass with marked osteolytic skull destruction and extension into the superior sagittal sinus with leptomeningeal enhancement. Systemic evaluation revealed multi-organ involvement, including bone marrow infiltration, leading to a diagnosis of stage IV DLBCL with secondary cutaneous involvement. Immunohistochemical analysis demonstrated expression of receptor activator of nuclear factor-κB ligand (RANKL) in tumor cells. The patient was treated with Pola-R-CHP followed by CNS-directed therapy, including high-dose methotrexate and intrathecal chemotherapy. The tumor showed marked regression, accompanied by improvement of neurological symptoms. This case highlights a rare presentation of DLBCL with skull destruction and suspected CNS involvement. Tumor-associated RANKL expression may be associated with the osteolytic features observed in this case. Early biopsy and systemic evaluation of cutaneous lesions are essential, as they may reflect aggressive systemic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.